Autumn Meeting 2015

 Industrial Group Autumn Meeting 2015


This year’s Industrial Group Autumn meeting took place on 12th November 2015 and was held at AstraZeneca, Macclesfield. The day consisted of seven talks from various academic and industrial speakers, themed around the issue of “Cracking Challenging Crystals”.


The first session, chaired by Helen Blade (AstraZeneca), was entitled “Crystallisation Control” and began with a talk from Nick Blagden from the University of Lincoln. His work outlined the use of micro channels for anti-solvent crystallisation, highlighting the importance of channel design in the control of liquid-liquid interfaces, a key parameter for particle development. In tandem to this, he also spoke about the challenges of using surfactants in order to further control crystal growth.


Next, Iain Oswald from the University of Strathclyde discussed the use of anti-solvent crystallisation in the production of multi-component species of l-amino acids, the solid-solutions of which were shown to have subtle differences in their infra-red spectra. The bulk production of such systems was then developed through the use of continuous anti-solvent crystallisation.


The morning session concluded with Kenneth Lewtas from Lewtas Science & Technologies Ltd. Kenneth spoke about his background in a variety of fields, discussing the use of specific crystal modification additives for a range of applications. His work focused on the control or prevention of crystallite formation, arching over several industries including pharmaceuticals, diesel fuels, adhesives and polymers.


After a hearty lunch, the session on “Structure Solution”, chaired by Cheryl Doherty (Pfizer), was opened by a talk from Andrew Bond from the University of Cambridge. Andrew outlined his extensive research in the field of crystal engineering, utilising it for enhanced property control. He went on to discuss the implications of polytypism, using the examples of aspirin, piroxicam and felodipine, demonstrating the ability of nanoindentation techniques for distinguishing between such forms.


Andrew was followed by Andy Stewart from the University of Limerick. He presented his extensive work in the field of electron diffraction tomography, a useful technique for structure determination using crystals of insufficient size for X-ray diffraction. Current advances include the structure determination of carbamazepine from a 10nm crystal, demonstrating the advantages of electron diffraction for allowing detection at the very limits of crystallinity.


The day concluded with “Complementary Tools in Pharmaceuticals”, chaired by Les Hughes (AstraZeneca). Steve Cosgrove, also from AstraZeneca, reminded us of the importance of understanding the link between structure and properties. He laid out the uses of structural informatics in the context of the pharmaceutical journey, presenting examples from AstraZeneca.


Steven P. Brown from the University of Warwick completed the lecture programme with his talk about NMR crystallography. He demonstrated the advances in solid-state NMR in conjunction with the pharmaceutical industry, outlining the applications of two-dimensional 1H, 1H-1H double quantum and 14N-1H experiments for the identification and characterisation of intermolecular interactions within solid structures. This was outlined with examples of indomethacin as well as in indomethacin-nicotinamide co-crystals.


Overall, it was a very informative and enjoyable day. Thank you to the organisers and the sponsors: AstraZeneca, Bruker and Pfizer.


Alex Cousen, Ruth Lunt and Anneke Klapwijk (University of Bath)

Helen Blade,
15 Oct 2015, 03:30
Helen Blade,
1 Oct 2015, 08:59
Helen Blade,
18 Oct 2015, 23:47